The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Update of a phase III trial of adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC).
He Jie
No relevant relationships to disclose
Baohui Han
No relevant relationships to disclose
Yongyu Liu
No relevant relationships to disclose
Shi Xiu Wu
No relevant relationships to disclose
Yukang Kuang
No relevant relationships to disclose
Yi Shen
No relevant relationships to disclose
Chun Chen
No relevant relationships to disclose
Qun Wang
No relevant relationships to disclose
Qiang Li
No relevant relationships to disclose
Ma Haitao
No relevant relationships to disclose
Shaofa Xu
No relevant relationships to disclose
Shidong Xu
No relevant relationships to disclose
Ping Wang
No relevant relationships to disclose
Weimin Mao
No relevant relationships to disclose
Zuoliang Pang
No relevant relationships to disclose
Shengcai Hou
No relevant relationships to disclose
Yue Yang
No relevant relationships to disclose